• 1
    Kilbourne AM, Justice AC, Rabeneck L, Rodriguez-Barradas M, Weissman S. VACS 3 Project Team. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001; 54 (Suppl 1): S22S28.
  • 2
    Justice AC, McGinnis KA, Atkinson JH et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: veterans aging cohort five-site study. AIDS 2004; 18 (Suppl 1): S49S59.
  • 3
    Pence BW, Miller WC, Whetten K, Enron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern United States. J Acquir Immune Defic Syndr 2006; 42: 298306.
  • 4
    Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725730.
  • 5
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 21012107.
  • 6
    Lima VD, Geller J, Bangsberg DR et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007; 21: 11751183.
  • 7
    Ickovics JR, Hamburger ME, Vlahov D et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 14661474.
  • 8
    Anastos K, Schneider MF, Gange SJ et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005; 39: 537544.
  • 9
    Parienti JJ, Massari V, Descamps D et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38: 13111316.
  • 10
    Cook JA, Grey D, Burke J et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94: 11331140.
  • 11
    Starace F, Bartoli L, Aloisi MS et al. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand 2002; 106: 2026.
  • 12
    Low-Beer S, Chan K, Yip B et al. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000; 23: 295301.
  • 13
    O'Mahony SM, Myint AM, Steinbusch H, Leonard BE. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation 2005; 12: 293298.
  • 14
    Muñoz-Moreno JA, Fumaz CR, Ferrer MJ et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev 2009; 11: 103109.
  • 15
    Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev 2010; 12: 6775.
  • 16
    Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick R. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009; 10: 343355.
  • 17
    Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4: 6266.
  • 18
    Fumaz CR, Muñoz-Moreno JA, Moltó J et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005; 38: 560565.
  • 19
    Clifford DB, Evans S, Yang Y et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143: 714721.
  • 20
    Gutiérrez F, Navarro A, Padilla S et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy using therapeutic drug monitoring. Clin Infect Dis 2005; 41: 16481653.
  • 21
    European Agency for the Evaluation of Medicinal Products. European Public Assessment Report: summary of product characteristics, SUSTIVA. 2009. Available at: (accessed 11 September 2013).
  • 22
    Marcellin F, Moh R, Carrieri MP et al. Depressive symptoms and exposure to efavirenz in West African HIV-infected adults. HIV Clin Trials 2008; 9: 445447.
  • 23
    Journot V, Chene G, De Castro N et al. ALIZE Study Group. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis 2006; 42: 17901799.
  • 24
    Masiá M, Padilla S, Alvarez D et al. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. AIDS 2013; 27: 181189.
  • 25
    Sobrino-Vegas P, Gutiérrez F, Berenguer J et al. The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up. Enferm Infecc Microbiol Clin 2011; 29: 645653.
  • 26
    Barak O, Goshen I, Ben-Hur T, Weidenfeld J, Taylor AN, Yirmiya R. Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein120. Brain Res 2002; 933: 98108.
  • 27
    Lawson MA, Kelley KW, Dantzer R. Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2, 3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav Immun 2011; 25: 15691575.
  • 28
    Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 4656.
  • 29
    Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36: 426436.
  • 30
    Fu X, Zunich SM, O'Connor JC, Kavelaars A, Dantzer R, Kelley KW. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation 2010; 7: 43.
  • 31
    O'Connor JC, Lawson MA, André C et al. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009; 182: 32023212.
  • 32
    O'Connor JC, Lawson MA, Andre C et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Mol Psychiatry 2009; 14: 511522.
  • 33
    Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214: 231241.
  • 34
    Fuchs D, Möller AA, Reibnegger G, Stöckle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3: 873876.
  • 35
    Waters L, Fisher M, Winston A et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011; 25: 6571.
  • 36
    Nguyen A, Calmy A, Delhumeau C et al. Swiss HIV Cohort Study. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011; 25: 5763.
  • 37
    Nguyen A, Calmy A, Delhumeau C et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011; 25: 14811487.